Bassermann, Florian

The target landscape of clinical kinase drugs

Klaeger, S., Heinzlmeir, S., Wilhelm, M., Polzer, H., Vick, B., Koenig, P.-A., Reinecke, M., Ruprecht, B., Petzoldt, S., Meng, C., et al. (2017) · Science

Computational Drug Discovery MethodsAdvanced Proteomics Techniques and Applications

Cited by 854

The Cdc14B-Cdh1-Plk1 Axis Controls the G2 DNA-Damage-Response Checkpoint

Bassermann, F., Frescas, D., Guardavaccaro, D., Busino, L., Peschiaroli, A., & Pagano, M. (2008) · Cell

DNA Repair MechanismsMicrotubule and mitosis dynamics

Cited by 397

JHDM1B/FBXL10 is a nucleolar protein that represses transcription of ribosomal RNA genes

Frescas, D., Guardavaccaro, D., Bassermann, F., Koyama-Nasu, R., & Pagano, M. (2007) · Nature

Epigenetics and DNA MethylationGenomics and Chromatin Dynamics

Cited by 284

Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity

Eichner, R., Heider, M., Fernández-Sáiz, V., van Bebber, F., Garz, A.-K., Lemeer, S., Rudelius, M., Targosz, B.-S., Jacobs, L., Knorn, A.-M., et al. (2016) · Nature Medicine

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 183

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)

Krönke, J., Kuchenbauer, F., Kull, M., Teleanu, V, Bullinger, L., Bunjes, D., Greiner, A., Kolmus, S., Köpff, S., Schreder, M., et al. (2017) · Leukemia

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 46

A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer

Lier, S., Sellmer, A., Orben, F., Heinzlmeir, S., Krauß, L., Schneeweis, C., Hassan, Z., Schneider, C., Patricia Gloria Schäfer, A., Pongratz, H., et al. (2022) · Bioorganic Chemistry

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 37

Proteomic analyses identify targets, pathways, and cellular consequences of oncogenic KRAS signaling

Kabella, N., Bayer, F. P., Stamatiou, K., Abele, M., Sakhteman, A., Chang, Y.-C., Wagner, V., Gabriel, A., Krumm, J., Reinecke, M., et al. (2025) · Science Signaling

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 8

Illuminating oncogenic KRAS signaling by multi-dimensional chemical proteomics

Kabella, N., Bayer, F. P., Stamatiou, K., Abele, M., Sakhteman, A., Chang, Y.-C., Wagner, V., Gabriel, A., Krumm, J., Reinecke, M., et al. (2025) · Science Signaling

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 8